From Harmony Bio and Inhibrx Raise Combined $247M in Public Market Debuts:

Harmony Biosciences and Inhibrx joined the Nasdaq exchange this week, two of a trio of biotechs slated to IPO.
Harmony Biosciences and Inhibrx joined the Nasdaq exchange this week, two of a trio of biotechs slated to IPO.

Image: iStock/Ja’Crispy